Flosequinan

Summary

Flosequinan (CHEMBL1908307) is an approved small molecule (ATC C01DB01); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01DB01
• Indications: 1 condition
• Chemistry: 239.27 Da · C11H10FNO2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1908307
Name	Flosequinan
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4474062
ATC	C01DB01
Molecular formula	C11H10FNO2S
Molecular weight	239.27
InChIKey	UYGONJYYUKVHDD-UHFFFAOYSA-N

SMILES: CN1C=C(C(=O)C2=C1C=C(C=C2)F)S(=O)C

IUPAC name: 7-fluoro-1-methyl-3-methylsulfinylquinolin-4-one

Also known as: BTS 49 465, BTS-49465, Flosequinan, Manoplax, FLOSEQUINAN, SID144206866, flosequinan

Patent coverage: 356 distinct patent families (1,279 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).